Mode
Text Size
Log in / Sign up
N/A N=65 Diagnostic

Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants

Preterm Infant · Early-Onset Neonatal Sepsis · Umbilical Cord

Enrolled (actual)
65
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcome: Primary: White Blood Cell Count (WBC) (1) — 8257 ratio of cells/mm3

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Placental/Umbilical Cord Blood sample (Other)
Age
Pediatric
Sex
All
Sponsor
The University of Texas Medical Branch, Galveston
Primary completion
Jun 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
White Blood Cell Count (WBC) (1)
8257
PRIMARY
White Blood Cell Count (WBC) (1) INFANT BLOOD
7055
PRIMARY
I/T Ratio (Immature/Total Immature Neutrophil).I/T Ratio Was Calculated by Dividing Immature White Cell Count Total White Cell Count
0.09
PRIMARY
I/T Ratio (Immature/Total Immature Neutrophil Ratio) INFANT BLOOD
0.12
PRIMARY
CRP (C-Reactive Protein)(1)
413
PRIMARY
CRP (C-Reactive Protein)(2) INFANT BLOOD
785
PRIMARY
IL-6 (1)
61.45; 45.36
PRIMARY
IL-6 (Interleukin-6) INFANTS BLOOD
45.36
PRIMARY
Procalcitonin PUBC
185.9
PRIMARY
Procalcitonin Level Was Measured in the Blood From Placenta and From the Baby Within 6 Hours After Birth
131.4
PRIMARY
Number of Participants With Negative Blood Culture From Blood Drawn From Placenta and From Baby Within 6 Hours After Birth
65
PRIMARY
Presepsin- PUBC
4.6
PRIMARY
Presepsin-Infant's Blood
5.3
PRIMARY
Number of Participants With a Negative Blood Culture
65

Summary

This study evaluates the utility of placental/umbilical cord blood (PUCB) to perform the baseline workup testing for EONS in Very Low Birth Weight Infants: CBC (Complete Blood Count) with differential, Immature/Total ratio (I/T ratio), and blood culture along with CRP and IL-6 levels. A cohort (63 subjects) of preterm infants will be recruited. All the participants will be evaluated for sepsis using placental/umbilical cord blood (PUCB) and subject blood sample during the first 12 hours of life (after birth).

Eligibility Criteria

Inclusion Criteria

  • Infants <34 weeks' gestational

Exclusion Criteria

  • Known congenital or chromosomal anomalies
  • Congenital heart disease (other than Patent Ductus Arteriosus, Patent Foramen Ovale or Atrial Septum Defect)
  • Vaginal bleeding at admission
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03694613). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search